Elective Bowel Resection for Incurable Stage IV Colorectal Cancer: Prognostic Variables for Asymptomatic Patients
- 1 May 2003
- journal article
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 196 (5) , 722-728
- https://doi.org/10.1016/s1072-7515(03)00136-4
Abstract
Surgical resection of primary colorectal cancer (CRC) in patients with stage IV disease at initial presentation remains controversial. Although bowel resection to manage symptoms such as bleeding, perforation, or obstruction has been advocated, management of asymptomatic patients has not been well defined. Patient-dependent factors (performance status, comorbid disease) and extent of distant metastases are among the considerations that impact on the decision to proceed with surgical management in asymptomatic stage IV CRC patients. We postulated that selected patients might benefit from elective resection of the asymptomatic primary CRC. The extent of distant metastases was objectively measured by several methods to identify potential prognostic variables that may help guide patient selection in this population. We reviewed hospital and colorectal service databases for the years 1996 to 1999. Stage IV patients who had colorectal resections with gross residual metastatic disease were identified (n = 209). Among these 209 patients, 82 patients operated on for symptoms (obstruction, perforation, bleeding, or pain) were excluded, leaving 127 patients who underwent elective resection of their asymptomatic primary CRC. Over the same time period, 103 stage IV patients who did not undergo resection were identified. Data on patient characteristics and clinical management were collected. A radiologist performed an independent review of available CT scans to assess extent of liver disease. The chi-square test was used for analysis of categoric data and Student's t-test for continuous variables. Survival was determined by the Kaplan-Meier method and distributions compared by the log rank test. Multivariate analysis was performed using Cox regression. The resected group could be easily distinguished from the nonresected group by a higher frequency of right colon cancers (p = 0.03) and metastatic disease restricted to the liver (p = 0.02) or one other site apart from the primary tumor (p = 0.02). Resected patients had prolonged median (16 versus 9 months, p < 0.001) and 2-year (25% versus 6%, p < 0.001) survival compared with patients never resected. Univariate analysis identified three significant prognostic variables (number of distant sites involved, metastases to liver only, and volume of hepatic replacement by tumor) in the resected group. Volume of hepatic replacement was also a significant predictor of survival in Cox multivariate regression analysis (p = 0.01). Subsequent to resection of asymptomatic primary CRC, 26 patients (20%) developed postoperative complications. Median hospital stay was 6 days. Two patients (1.6%) died within 30 days of surgery. Stage IV patients selected for elective palliative resection of asymptomatic primary colorectal cancers had substantial postoperative survival that was significantly better than those never having resection. Limited metastatic tumor burden and less extensive liver involvement were associated with better survival and a higher likelihood of benefit from elective bowel resection in asymptomatic patients with incurable stage IV CRC.Keywords
This publication has 13 references indexed in Scilit:
- Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV diseaseAnnals of Surgical Oncology, 2002
- Nephrectomy Followed by Interferon Alfa-2b Compared with Interferon Alfa-2b Alone for Metastatic Renal-Cell CancerNew England Journal of Medicine, 2001
- Non-operative management of the primary tumour in patients with incurable stage IV colorectal cancerBritish Journal of Surgery, 2001
- Answering Patients' Needs: Oral Alternatives to Intravenous TherapyThe Oncologist, 2001
- Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III StudyJournal of Clinical Oncology, 2001
- Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2000
- Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal CancerJournal of Clinical Oncology, 2000
- Initial Presentation With Stage IV Colorectal CancerArchives of Surgery, 2000
- Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trialPublished by Elsevier ,2000
- Operation in patients with incurable colon cancer—Is it worthwhile?Diseases of the Colon & Rectum, 1997